Pharma & Bio
Technology
Holding Company Plummets After AriBio Withdraws Merger… HLB PHARMACEUTICAL Jumps 63% in Two Days [Bio Spotlight]
On the 29th, #AriBioHoldings announced it was withdrawing the absorption merger with AriBio, a plan it had been pursuing for over two years, causing its stock to plummet to the daily lower limit in af…
- 2026-10-01 06:41:02
- Kim Seung-kwon
Technology
Kolmar Korea Acquires Blue M-Tech… From ‘AI and Data’-Based Distribution to Synergies with HK Innoen
#Kolmar Korea Holdings is drawing attention as it moves to acquire #Blue M Tech, a pharmaceutical distribution platform company. This move is interpreted as an effort by the Kolmar Group—which special…
- 2026-09-30 08:36:02
- KIM SUNG-JIN
Technology
Taking on Japan’s Olympus… ‘Korean AI-Powered Endoscope’ Picked by Seoul National University Professor [Expert Insight]
Endoscopic examinations place a significant physical strain on medical staff. They must operate the controls—which weigh over 600g—using their fingers and wrists, and in the case of therapeutic endosc…
- 2026-09-30 08:33:02
- Hong Ju-yeon
Lifestyle
Investor Sentiment Rebounds; HLB, VUNO, and BNC Korea Drive Market Turning Point [K-Bio Pulse]
The driving force behind the KOSDAQ rebound on the 28th was the pharmaceutical, biotechnology, and medical device (bio) sector, led by the HLB Group. Overcoming macroeconomic uncertainties and a prolo…
- 2026-09-30 08:01:03
- YU JIN-HEE
Lifestyle
Investor Sentiment Returns… Focus on Inflection Points for HLB INC., VUNO, and BNC KOREA [Bio Spotlight]
On the 28th, the pharmaceutical, biotech, and medical device (bio) sectors—led by HLB Group—were the driving force behind the KOSDAQ market’s rebound. Breaking through macroeconomic uncertainty and a …
- 2026-09-30 08:01:02
- YU JIN-HEE
Technology
The Path for “Once-a-Month Weight-Loss Drugs” Widens… Viking’s Success Puts Korean Long-Acting Drug Industry on Edge
U.S.-based Viking Therapeutics has proposed the possibility of a once-monthly weight-loss drug without the need for a separate long-acting formulation technology. From the perspective of domestic deve…
- 2026-09-30 07:07:02
- KIM SAE-MI
Technology
Next-Generation Osteoarthritis Treatment Emerges as a Rising Star... Kim Dae-won, CEO of ICM: "We’ve Addressed Both Structural Issues and Pain"
“For osteoarthritis treatments, simply reducing pain is not enough. They must also restore damaged joint structures, reduce inflammation, and demonstrate that patients actually experience less pain an…
- 2026-09-29 08:56:02
- Kim Seung-kwon
Lifestyle
Vaxcell-Bio Therapeutics: Why It Filed for a ‘Clinical Trial’ Despite Risk Adjustments for VCB-1102
Vaxcell-Bio Therapeutics(323990)is launching additional clinical trials, including a controlled study, to enter the market for the treatment of advanced liver cancer with its core pipeline product, th…
- 2026-09-29 08:16:02
- Kim Jinsoo
Technology
RNA Editing Heats Up: Why Are Anticancer Drugs So Rare?…Rznomics Inc.’s Indirect Strategy
The global competition for new RNA-editing drugs is now fully entering the clinical trial phase. However, major companies’ development efforts remain focused on rare and genetic diseases. This is why …
- 2026-09-29 08:06:02
- NA EUN-KYUNG
Technology
Proteina Rises on AI Data...Ingenia Advances to Phase 3 [K-Bio Pulse]
South Korea’s pharmaceutical and life sciences sectors moved in opposite directions on Sept. 23. The life sciences sector rose 0.64%, while the pharmaceutical sector fell 0.45%.
(Graphic by ChatGPT…
- 2026-09-29 07:32:02
- KIM JI-WAN
PHARM EDAILY
Shorts